Cognitive Control Training for Obsessive-Compulsive Disorder
Trial Summary
Yes, participants must not be on psychotropic medication and should be free of such medication for at least three months before joining the trial.
Research suggests that combining self-directed exposure therapy with Cognitive Bias Modification (CBM) can significantly reduce OCD symptoms, indicating that similar cognitive training approaches may be effective. Additionally, cognitive-behavioral therapy (CBT) is a well-established treatment for OCD, and innovative computerized tools have been explored to enhance its efficacy.
12345Cognitive Control Training (CT) is unique because it uses a computerized approach to enhance cognitive control, which may help manage obsessive-compulsive disorder (OCD) symptoms by targeting the brain's ability to regulate thoughts and behaviors. This differs from traditional treatments like cognitive-behavioral therapy (CBT) and exposure with response prevention (ERP), which focus more on behavioral changes and exposure to fears.
12567Eligibility Criteria
This trial is for children aged 8-12 with clinically significant OCD as their main issue, not on medication or psychotherapy for OCD. They must meet specific criteria and have a score of ≥16 on the C-YBOCS scale. Kids can't join if they're pregnant, nursing, use illicit drugs, have metal implants/braces, major depression or other serious mental disorders, suicidal thoughts, major medical issues or an IQ <80.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Cognitive Training
Participants receive 4 weeks of at-home computerized cognitive training program (AKL-T01) delivered on iPad
Cognitive Behavioral Therapy
Participants are offered a 12-week course of gold-standard Cognitive Behavioral Therapy with exposure and response prevention
Follow-up
Participants are monitored for safety and effectiveness after treatment
Participant Groups
Cognitive Control Training (CT) is already approved in United States for the following indications:
- Attention Deficit Hyperactivity Disorder (ADHD)